• If you are wondering whether Arrowhead Pharmaceuticals at around US$77.95 is still offering value or has already run too far, this breakdown is designed to help you frame that question clearly.
• The stock has returned 6.1% over the past week, 27.4% over the last 30 days, 15.0% year to date, and 488.3% over the past year, which naturally raises questions about how much of the story is already priced in.
• Recent coverage has focused on Arrowhead Pharmaceuticals' progress in RNA interference based therapies and its broader development pipeline. This has given investors more detail on how the business model might evolve. At the same time, ongoing commentary around partnership activity and the competitive biotech space has added context to the share price moves.
• Even after these moves, Arrowhead Pharmaceuticals earns a valuation score of 2 out of 6. The next sections will walk through how different valuation approaches treat the stock, before finishing with a way to think about valuation that brings those methods together in a more complete view.

Arrowhead Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Arrowhead Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and discounting them back to today to reflect time and risk. For Arrowhead Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections.

The latest twelve month Free Cash Flow is reported at $79.13 million. Analyst inputs and subsequent projections, provided in dollar terms, extend out to 2035 and include both expected losses and positive Free Cash Flow figures. For example, Simply Wall St cites a projected Free Cash Flow of $354.85 million for 2030, with further years extrapolated beyond the period where analysts typically provide estimates.

Pulling these discounted cash flows together results in an estimated intrinsic value of $162.59 per share. Against a current share price of about $77.95, the model implies the stock is 52.1% undervalued based on these assumptions and inputs.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Arrowhead Pharmaceuticals is undervalued by 52.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Arrowhead Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful shorthand because it connects what you pay for the stock with the earnings the company is currently generating. It gives you a simple way to judge how much the market is willing to pay for each dollar of earnings.

What counts as a “normal” P/E depends heavily on expectations and risk. Higher growth expectations or lower perceived risk can support a higher P/E, while lower growth or higher uncertainty usually line up with a lower figure.

Arrowhead Pharmaceuticals currently trades on a P/E of 54.0x. That is higher than the Biotechs industry average P/E of about 17.7x and also above the peer group average of 28.5x. Simply Wall St’s Fair Ratio for Arrowhead Pharmaceuticals is 17.0x. This Fair Ratio is a proprietary estimate of what the P/E might be, given factors such as earnings growth, industry, profit margin, market cap and key risks.

The Fair Ratio can be more informative than a simple industry or peer comparison because it incorporates company specific characteristics rather than just grouping all biotechs together. Compared with the current P/E of 54.0x, the Fair Ratio of 17.0x suggests the stock is trading above that fair level on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Arrowhead Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives on Simply Wall St let you link your view of Arrowhead Pharmaceuticals' story to explicit forecasts and a Fair Value. You can, for example, consider whether you think the stock belongs closer to the bullish US$110 fair value with assumptions like a 7.22% discount rate and earnings of US$179.9 million by 2029, or nearer the bearish US$42.57 fair value with a 7.27% discount rate and earnings of US$49.1 million. You can then compare that Fair Value with the current price to decide whether the stock looks expensive or cheap right now.

For Arrowhead Pharmaceuticals, however, we will make it really easy for you with previews of two leading Arrowhead Pharmaceuticals narratives:

Start by asking which camp you lean toward, then see how that lines up with the current share price and the earlier DCF and P/E work.

Here are two contrasting narratives to pressure test your own view of the stock.

Fair value in this bullish narrative: US$110.00 per share.

At a last close of US$77.95, that implies the stock is about 29% below this fair value anchor.

Revenue growth assumption: 1.22% annual revenue contraction over the next 3 years.

• Bullish analysts think cardiometabolic RNAi data, global launches like plozasiran and a broadening multi organ RNAi platform could justify a higher long term earnings profile than the market is currently pricing.
• They also see large potential milestone payments from partners such as Sarepta and Sanofi, plus regular new wholly owned candidates entering the clinic, as key supports for non dilutive cash inflows and pipeline depth.
• To reach the US$110 target, this view requires confidence in US$1.1b of revenue and US$179.9m of earnings by 2029, along with the market accepting a P/E of about 110x on those earnings.

Fair value in this bearish narrative: US$42.57 per share.

At a last close of US$77.95, that implies the stock is about 83% above this fair value anchor.

Revenue growth assumption: 32.78% annual revenue contraction over the next 3 years.

• Bearish analysts are more focused on reimbursement pressure, potential regulatory shifts for genetic medicines and the risk that RNAi is squeezed by cheaper generics and newer gene editing approaches.
• They see heavy dependence on a small set of RNAi assets and external partners as a source of earnings volatility if any late stage program, deal or pricing assumption does not go to plan.
• To reach the US$42.57 target, this view assumes revenue falls to about US$331.3m and earnings to US$49.1m by 2029, with the stock still trading on a very high P/E of around 156x at that point.

Put simply, the bullish and bearish narratives are anchored on very different earnings paths and valuation multiples, so your own stance on Arrowhead Pharmaceuticals comes down to which story you find more realistic and how comfortable you are with the risks on each side.

See what the community is saying about Arrowhead Pharmaceuticals.

Do you think there's more to the story for Arrowhead Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.